ESCRT-III Complex: Drug Targets and Potential Therapeutic Applications

Target Name: ESCRT-III complex

NCBI ID: P25056

Other Name(s): Endosomal sorting required for transport complex III (ESCRT-III)

ESCRT-III Complex: Drug Targets and Potential Therapeutic Applications

The ESCRT-III complex is a protein complex that plays a crucial role in the endosomal system, which is responsible for the transport of various cellular and viral materials from the cytoplasm to the endoplasmic reticulum for degradation or storage. The ESCRT-III complex is composed of several proteins that work together to ensure the efficient sorting of different cellular and viral materials into the endoplasmic reticulum. One of the proteins in the complex is ESCRT-III itself, while the other proteins in the complex include Jinshi Research Enzyme (JNJ-752692) , known as p120GAP, and transport factor (TMJ-1), among others.

The ESCRT-III complex is responsible for the delivery of various materials to the endoplasmic reticulum, including but not limited to:

* vesicles containing cytoplasmic enzymes, such as activating transcription factor 3 (ATF-3) and heat shock protein 70 (Hsp70), which are involved in the intracellular signaling pathway known as the TGF-β pathway.
* viruses and other small packages that are released during cellular stress, such as adeno-associated viruses (AAVs) and SARS-CoV-2.
* organelles that are damaged or exchanged during cellular processes, such as mitochondrial organelles and endoplasmic reticulum-localized proteins.

The ESCRT-III complex plays a vital role in the endosomal system by ensuring the efficient delivery of these materials to the endoplasmic reticulum for degradation or storage. However, the complex can also be modified by various diseases, including neurodegenerative diseases, cancer, and infectious diseases.

The ESCRT-III complex is a protein complex that can be targeted by drugs as a potential therapeutic approach for various diseases. One such drug that has been shown to target the ESCRT-III complex is JNJ-752692, also known as p120GAP. JNJ- 752692 is a potent inhibitor of the protein kinase PDK4, which is a key enzyme involved in the ESCRT-III complex.

In neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease, the ESCRT-III complex is often disrupted, leading to the accumulation of damaged proteins and organelles in the endoplasmic reticulum. By inhibiting the activity of PDK4, JNJ-752692 has been shown to protect against neurodegeneration and improve the survival of neurodegenerative disease models in animal models.

In addition to its potential therapeutic applications, JNJ-752692 also has the potential to be used as a biomarker for neurodegenerative diseases. By measuring the levels of JNJ-752692 in brain tissue or fluids, researchers can monitor the effectiveness of JNJ-752692 as a therapeutic agent and track the progression of neurodegenerative diseases.

Another drug that has been shown to target the ESCRT-III complex is TMJ-1, a protein that is involved in the formation of the endosomal system. TMJ-1 is a key component of the ESCRT-III complex, and its activity is required for the efficient delivery of various materials to the endoplasmic reticulum.

TMJ-1 has been shown to play a crucial role in the development and progression of various diseases, including neurodegenerative diseases. By inhibiting the activity of TMJ-1, researchers have shown that they can improve the survival of neurodegenerative disease models in animal models.

In conclusion, the ESCRT-III complex is a protein complex that plays a crucial role in the endosomal system. It is involved in

Protein Name: ESCRT-III Complex

More Common Targets